Nicotinamide inhibits growth of carcinogen induced mouse bladder tumor and human bladder tumor xenograft through up-regulation of RUNX3 and p300

Journal of Urology

Volumn 185, Issue 6, 2011, Pages 2366-2375

  Kim, Wun Jae ^a   Lee, Jung Won ^b   Quan, Changyi ^d   Youn, Hyung Joon ^b   Kim, Hwan Mook ^c   Bae, Suk Chul ^b  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chungbuk National University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

acetylation; mouse; nicotinamide; Runx3 protein; urinary bladder; urinary bladder neoplasms

Indexed keywords

DOXORUBICIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; NICOTINAMIDE; PROTEIN P300; SIRTUIN 2; TRANSCRIPTION FACTOR RUNX3;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER SIZE; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOUSE; MUSCLE INVASIVE BLADDER CANCER; MUSCLE METASTASIS; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; TRANSACTIVATION; TUMOR XENOGRAFT; UPREGULATION; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DISEASE MODELS, ANIMAL; E1A-ASSOCIATED P300 PROTEIN; HUMANS; MICE; NIACINAMIDE; SIRTUIN 2; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 79955827893     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2011.02.017     Document Type: Article

References (30)

1. A.H. Lund, and M. van Lohuizen RUNX: a trilogy of cancer genes Cancer Cell 1 2002 213
2. F. Otto, A.P. Thornell, and T. Crompton Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development Cell 89 1997 765
3. T. Okuda, R. Fisher, and J.R. Downing Molecular diagnostics in pediatric acute lymphoblastic leukemia Mol Diagn 1 1996 139
4. S. Mundlos, and B.R. Olsen Heritable diseases of the skeleton Part I: molecular insights into skeletal development-transcription factors and signaling pathways FASEB J 11 1997 125
5. B. Lee, K. Thirunavukkarasu, and L. Zhou Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia Nat Genet 16 1997 307
6. A.T. Look Oncogenic transcription factors in the human acute leukemias Science 278 1997 1059
7. K. Inoue, S. Ozaki, and T. Shiga Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons Nat Neurosci 5 2002 946
8. I. Taniuchi, M.J. Sunshine, and R. Festenstein Evidence for distinct CD4 silencer functions at different stages of thymocyte differentiation Mol Cell 10 2002 1083
9. Q.L. Li, K. Ito, and C. Sakakura Causal relationship between the loss of RUNX3 expression and gastric cancer Cell 109 2002 113
10. W.J. Kim, E.J. Kim, and P. Jeong RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors Cancer Res 65 2005 9347
11. K. Ito, A.C. Lim, and M. Salto-Tellez RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis Cancer Cell 14 2008 226
12. K.S. Lee, Y.S. Lee, and J.M. Lee Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer Oncogene 29 2010 3349
13. C. Bangsow, N. Rubins, and G. Glusman The RUNX3 genesequence, structure and regulated expression Gene 279 2001 221
14. A. Balmain Cancer: new-age tumour suppressors Nature 417 2002 235
15. Y.H. Jin, E.J. Jeon, and Q.L. Li Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination- mediated degradation J Biol Chem 279 2004 29409
16. P.A. Marks, and W.S. Xu Histone deacetylase inhibitors: potential in cancer therapy J Cell Biochem 107 2009 600
17. S. Khochbin, A. Verdel, and C. Lemercier Functional significance of histone deacetylase diversity Curr Opin Genet Dev 11 2001 162
18. H. Vaziri, S.K. Dessain, and E. Ng Eaton hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase Cell 107 2001 149
19. J. Luo, A.Y. Nikolaev, and S. Imai Negative control of p53 by Sir2alpha promotes cell survival under stress Cell 107 2001 137
20. O. Grubisha, B.C. Smith, and J.M. Denu Small molecule regulation of Sir2 protein deacetylases FEBS J 272 2005 4607
21. R.W. Johnstone Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nat Rev Drug Discov 1 2002 287
22. R.M. Anderson, K.J. Bitterman, and J.G. Wood Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae Nature 423 2003 181
23. K.J. Bitterman, R.M. Anderson, and H.Y. Cohen Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1 J Biol Chem 277 2002 45099
24. Q.L. Li, H.R. Kim, and W.J. Kim Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer Biochem Biophys Res Commun 314 2004 223
25. X.Z. Chi, J. Kim, and Y.H. Lee Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination Cancer Res 69 2009 8111
26. G. Egger, G. Liang, and A. Aparicio Epigenetics in human disease and prospects for epigenetic therapy Nature 429 2004 457
27. M. Porcu, and A. Chiarugi The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension Trends Pharmacol Sci 26 2005 94
28. N.G. Iyer, H. Ozdag, and C. Caldas p300/CBP and cancer Oncogene 23 2004 4225
29. K. Maiese, Z.Z. Chong, and J. Hou The vitamin nicotinamide: translating nutrition into clinical care Molecules 14 2009 3446
30. S. Rajamanickam, and R. Agarwal Natural products and colon cancer: current status and future prospects Drug Dev Res 69 2008 460